Incremental net benefit in randomized clinical trials with quality‐adjusted survival

Owing to induced dependent censoring, estimating mean costs and quality-adjusted survival in a cost-effectiveness comparison of two groups using standard life-table methods leads to biased results. In this paper we propose methods for estimating the difference in mean costs and the difference in mean effectiveness, together with their respective variances and covariance in the presence of dependent censoring. We consider the situation in which the measure of effectiveness is either the probability of surviving a duration of interest or mean quality-adjusted survival time over a duration of interest. The methods are illustrated in an example using an incremental net benefit analysis.

[1]  D Y Lin,et al.  Incremental net benefit in randomized clinical trials , 2001, Statistics in medicine.

[2]  A R Willan,et al.  Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data. , 2001, Controlled clinical trials.

[3]  J. Mullahy,et al.  Valuing health care: Statistical issues in cost–effectiveness analyses , 1995 .

[4]  Testing Equality of Survival Functions of Quality‐Adjusted Lifetime , 2001, Biometrics.

[5]  A Briggs,et al.  Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.

[6]  Anastasios A. Tsiatis,et al.  Estimating medical costs with censored data , 2000 .

[7]  Andrew R. Willan,et al.  Incremental net bene ' t in randomized clinical trials , 2001 .

[8]  M Johannesson,et al.  A Note on Confidence Intervals in Cost-Effectiveness Analysis , 1998, International Journal of Technology Assessment in Health Care.

[9]  D Polsky,et al.  Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.

[10]  Bernie J. O'Brien,et al.  In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.

[11]  D. Lin,et al.  Linear regression analysis of censored medical costs. , 2000, Biostatistics.

[12]  R. Baltussen,et al.  The interpretation of results of economic evaluation: explicating the value of health. , 1997, Health economics.

[13]  E. M. Konst,et al.  UNCERTAINTY OF INCREMENTAL COST-EFFECTIVENESS RATIOS , 1999, International Journal of Technology Assessment in Health Care.

[14]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[15]  A R Willan,et al.  Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. , 1996, Health economics.

[16]  A H Briggs,et al.  Handling uncertainty in economic evaluations of healthcare interventions , 1999, BMJ.

[17]  M Gent,et al.  Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: Results From the Canadian Implantable Defibrillator Study (CIDS) , 2001, Circulation.

[18]  R. Gelber,et al.  Quality adjusted survival analysis. , 1990, Statistics in medicine.

[19]  Anastasios A. Tsiatis,et al.  A consistent estimator for the distribution of quality adjusted survival time , 1997 .

[20]  J C Gardiner,et al.  Power and sample assessments for tests of hypotheses on cost-effectiveness ratios. , 2000, Health economics.

[21]  J Mullahy.  What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. , 1996, Medical care.

[22]  A R Willan,et al.  Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. , 1999, Health economics.

[23]  Robert L. Strawderman,et al.  Estimating the Mean of an Increasing Stochastic Process at a Censored Stopping Time , 2000 .

[24]  A H Briggs,et al.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.

[25]  A H Briggs,et al.  Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. , 1999, Statistics in medicine.

[26]  P. Wakker,et al.  Confidence intervals for cost/effectiveness ratios. , 1995, Health economics.

[27]  Johan L. Severens,et al.  ECONOMIC EVALUATION OF DIAGNOSTIC TESTS , 1999, International Journal of Technology Assessment in Health Care.

[28]  A H Briggs,et al.  Power and Sample Size Calculations for Stochastic Cost-Effectiveness Analysis , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  E. Feuer,et al.  Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.

[30]  A H Briggs,et al.  A Bayesian approach to stochastic cost-effectiveness analysis. , 1999, Health economics.

[31]  D. Heitjan,et al.  Fieller's method and net health benefits. , 2000, Health economics.

[32]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[33]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[34]  S. Stearns,et al.  Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. , 1996, Statistics in medicine.

[35]  A A Tsiatis,et al.  Efficient Estimation of the Distribution of Quality‐Adjusted Survival Time , 1999, Biometrics.

[36]  J. Heyse,et al.  A regression-based method for estimating mean treatment cost in the presence of right-censoring. , 2000, Biostatistics.

[37]  A J Moskowitz,et al.  Bayesian estimation of cost-effectiveness ratios from clinical trials. , 1999, Health economics.

[38]  C E Phelps,et al.  On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses , 1991, International Journal of Technology Assessment in Health Care.

[39]  Morris Meisner,et al.  Power and Sample Size in Cost- Effectiveness Analysis , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.